Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bipolar Disorder01:30

Bipolar Disorder

616
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
616
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

596
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
596
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

466
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
466
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

545
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
545
CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

679
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
679
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

811
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
811

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study.

BMJ open·2026
Same author

Establishing a Specialty Bipolar Clinic: The National Network of Depression Centers Consensus Recommendations.

Bipolar disorders·2026
Same author

Decomposing neuroanatomical heterogeneity in depression: insights from an ENIGMA major depressive disorder working group study in 5146 individuals.

Translational psychiatry·2026
Same author

The Regional Vulnerability Index (RVI) as a Neuroimaging-Based Biomarker for Autism: Associations with Likelihood, Cognition, and Longitudinal Social Outcomes.

bioRxiv : the preprint server for biology·2026
Same author

Brain Morphology Mediators of the Association of Childhood Trauma With Bipolar Disorder: An International ENIGMA Bipolar Disorder Working Group Study.

JAMA psychiatry·2026
Same author

Response-predictive MRI biomarkers of low-dose lithium therapy: cortical thickness changes in patients with bipolar depression.

Psychiatry research. Neuroimaging·2026

Related Experiment Video

Updated: Jan 14, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

7.5K

Contemplating versus having used psychedelics in bipolar disorder - What makes the difference?

Lauren N Vale1, Maya Ibrahim2, Leonardo Fávaro-Pereira3

  • 1Louis A. Faillace Department of Psychiatry & Behavioral Sciences, UTHealth Houston, 1941 East Rd., Houston, TX 77054, USA.

Journal of Affective Disorders
|October 18, 2025
PubMed
Summary

Individuals with bipolar disorder (BD) who have used psychedelics show more positive attitudes and openness than those considering use. Previous psychedelic experience may shape perceptions and motivations for use in bipolar disorder patients.

Keywords:
Attitudes towards psychedelicsBipolar disorderMental health treatmentMood disordersMotivations for usePsychedelics

More Related Videos

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.2K
Exploring the Neural Correlates of Cognitive Reappraisal in Obsessive-Compulsive Disorder Using Task-based Functional Magnetic Resonance Imaging
09:14

Exploring the Neural Correlates of Cognitive Reappraisal in Obsessive-Compulsive Disorder Using Task-based Functional Magnetic Resonance Imaging

Published on: March 14, 2025

902

Related Experiment Videos

Last Updated: Jan 14, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

7.5K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.2K
Exploring the Neural Correlates of Cognitive Reappraisal in Obsessive-Compulsive Disorder Using Task-based Functional Magnetic Resonance Imaging
09:14

Exploring the Neural Correlates of Cognitive Reappraisal in Obsessive-Compulsive Disorder Using Task-based Functional Magnetic Resonance Imaging

Published on: March 14, 2025

902

Area of Science:

  • Psychiatry
  • Neuroscience
  • Psychopharmacology

Background:

  • Psychedelics show promise for mental health treatment.
  • Bipolar disorder (BD) patients are often excluded from psychedelic research due to concerns about adverse psychiatric events.
  • Understanding the motivations and characteristics of BD individuals considering psychedelics is crucial.

Purpose of the Study:

  • To explore the motivations, expectations, and personality traits of individuals with bipolar disorder (BD) who have previously used classic psychedelics (experimenters) versus those considering future use (contemplators).
  • To compare experimenters and contemplators on sociodemographic, psychological, and mental health variables.

Main Methods:

  • Observational study comparing two groups: individuals with BD who have used psychedelics (experimenters) and those considering using them (contemplators).
  • Assessment of sociodemographic, psychological, and mental health variables.
  • Comparison of attitudes, motivations, expectations, and personality characteristics between the two groups.

Main Results:

  • Experimenters and contemplators did not differ in sociodemographic or mental health variables.
  • Experimenters exhibited more positive attitudes towards psychedelics and higher "openness to experience" compared to contemplators.
  • Specific motives for psychedelic use were more strongly endorsed by experimenters, while contemplators expressed greater concerns about potential negative effects.

Conclusions:

  • Previous psychedelic experience in individuals with bipolar disorder is associated with more positive perceptions and stronger motivations for use.
  • Personality traits, particularly "openness to experience," may differentiate those who have used psychedelics from those who are considering them.
  • Findings inform discussions regarding psychedelic use in individuals with BD, even within clinical trial contexts, highlighting areas for risk-benefit assessment and patient counseling.